The results revealed that the isolated 6-methoxykynurenic acid (6-mKYNA) could be a promising new agent for the treatment of breast cancer, and that 6-mKYNA can directly inhibit CA-19.9 and CA-125 tumor biomarkers. Here, MUC16 is linked to breast cancer.